EXAS Value Score

3

24

15

Average Growth
  • AI analysis rates EXAS  with a medium value score of 3.
  • It is mainly due to  adequate safety shown in the balance sheet, but with concerns regarding unstable operating cash flow.
  • Over the past 3 months, EXAS has maintained an average value rating of 3.3, close to the rating of 3.0 over the past 3 years, indicating stable enterprise value.
  • Compared to all stocks in the Health Care sector, EXAS has a medium value rating.

EXAS Value Reference Factors

The Value score is derived from various data and factor information, integrated through AI algorithms. The following factors are part of the evaluation used by AI value scores.

Update to 2023/07/13 (Weekly Update)

EXAS Financial Forecast

Unit : USD

Update to 2024/7/27 (Quarterly Update)

EXAS Earnings Table

Unit : USD

QTREPSEPS YoYEPS Surprise %SalesSales YoYSales Surprise %NPM
Current
-0.6
-42.9%
-27.4%
637.52M
5.8%
1.6%
-17.3%
2023Q4
-0.27
62.5%
41.2%
646.89M
17%
1.3%
-7.7%
2023Q3
0
100%
100%
628.34M
20.1%
1.9%
0.1%
2023Q2
-0.45
45.8%
11.7%
622.09M
19.3%
3.7%
-13%
2023Q1
-0.42
59.6%
44.2%
602.45M
23.8%
10.9%
-12.3%

Update to 2024/7/27 (Quarterly Update)

EXAS Historical Value Score

You can use historical scores of 3 or above to observe potential performance and make investment decisions.

EXAS Value Strategy Backtest

The following backtest is based on specified rules since 2007. Price chart shows buy/sell time, cumulative returns, and backtesting statistics.

Entry
Exit

The Backtest Result of EXAS from 2007/01 till Now

750.83%
Cumulative Return
12.99%
Annual Return
38.11%
Volatility
0.34
Sharpe Ratio

Statistics data for entering at or above a Value score of 4 and exiting at or below a Value score of 2 from January, 2007 to July, 2024. (Total Trades: 5)

EXASSectorUS Overall Market
Wining Rate60%46%56%
Avg Return108.1%63.3%77.2%
Avg Profit205.3%187.7%166.4%
Avg Loss-37.7%-44.3%-34.5%
Avg Risk-Reward Ratio544.5%424%482.5%

Update to 2024/7/27 (Daily Update)

Top 10 High Relevance to EXAS Value Score